Bristol Myers Squibb Company (NYSE:BMY) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Bristol Myers Squibb Company (NYSE:BMY) have received a consensus rating of “Moderate Buy” from the twenty-five analysts that are covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, ten have given a hold recommendation, twelve have given a buy recommendation and two have given a strong buy recommendation to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $67.06.

A number of equities analysts recently weighed in on BMY shares. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $59.00 price objective (up from $54.00) on shares of Bristol Myers Squibb in a research report on Friday, July 31st. UBS Group cut Bristol Myers Squibb from a “buy” rating to a “neutral” rating in a research note on Wednesday, August 5th. Wall Street Zen raised Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research note on Saturday, June 27th. Royal Bank Of Canada increased their target price on Bristol Myers Squibb from $60.00 to $64.00 and gave the stock a “sector perform” rating in a research note on Friday, July 31st. Finally, TD Cowen began coverage on Bristol Myers Squibb in a report on Wednesday, August 5th. They set a “buy” rating for the company.

Trending Headlines about Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: The FDA expanded approval of CAMZYOS (mavacamten) to include pediatric patients with symptomatic obstructive hypertrophic cardiomyopathy. The broader eligible population could support additional product growth and strengthens BMY’s commercial outlook. FDA approves expanded CAMZYOS indication
• Positive Sentiment: Strong Phase 3 data for ZENBEXUS (iberdomide) in relapsed or refractory multiple myeloma showed a statistically significant improvement in minimal residual disease-negative complete responses, potentially supporting an accelerated approval path and future pipeline value. ZENBEXUS Phase 3 data
• Positive Sentiment: Bristol Myers Squibb declared a quarterly dividend of $0.63, reinforcing its income appeal, although future dividend growth depends on cash flow generation. BMY quarterly dividend
• Neutral Sentiment: Updates on real-world studies for AUGTYRO and luspatercept, along with broader healthcare-professional outreach, provide supportive commercial and clinical evidence but do not represent major new revenue catalysts yet.
• Neutral Sentiment: Johnson & Johnson continues to generate higher quarterly revenue than BMY, while both companies have shown generally gradual revenue growth. The comparison highlights BMY’s smaller scale but does not materially change its near-term earnings outlook. Bristol Myers Squibb versus Johnson & Johnson revenue comparison
• Negative Sentiment: BMY terminated an early-stage leukemia study, removing a risky pipeline bet but also signaling diminished prospects for that program. BMY terminates early leukemia trial
• Negative Sentiment: Testing of experimental fibrosis drug admilparant involved a limited number of liver-related safety events, including a patient death. Although causation remains unclear, the report undermines confidence in the program and the broader drug class. Bristol Myers trial revisions and fibrosis-drug safety concerns
• Negative Sentiment: Analysts and investors continue to focus on the potential 2027 patent cliff affecting BMY’s largest cash generator. The resulting pressure on future cash flow could challenge the company’s 17-year dividend-growth streak and weigh on valuation. Bristol Myers Squibb dividend sustainability concerns

Insider Activity at Bristol Myers Squibb

In related news, SVP Phil M. Holzer sold 500 shares of Bristol Myers Squibb stock in a transaction that occurred on Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total value of $33,750.00. Following the completion of the transaction, the senior vice president owned 16,862 shares in the company, valued at approximately $1,138,185. The trade was a 2.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 0.05% of the company’s stock.

Hedge Funds Weigh In On Bristol Myers Squibb

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Norges Bank acquired a new stake in Bristol Myers Squibb in the 4th quarter valued at about $1,947,272,000. Primecap Management Co. CA acquired a new position in shares of Bristol Myers Squibb during the second quarter worth about $1,436,115,000. Legal & General Group Plc purchased a new stake in shares of Bristol Myers Squibb during the second quarter worth approximately $980,862,000. BlackRock Inc. raised its holdings in Bristol Myers Squibb by 5.1% in the second quarter. BlackRock Inc. now owns 180,384,994 shares of the biopharmaceutical company’s stock valued at $10,393,783,000 after acquiring an additional 8,702,106 shares in the last quarter. Finally, Bank of New York Mellon Corp raised its holdings in Bristol Myers Squibb by 47.0% in the fourth quarter. Bank of New York Mellon Corp now owns 24,495,875 shares of the biopharmaceutical company’s stock valued at $1,321,308,000 after acquiring an additional 7,837,485 shares in the last quarter. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Bristol Myers Squibb Stock Down 1.6%

Shares of NYSE:BMY opened at $61.40 on Friday. The company has a market capitalization of $125.42 billion, a price-to-earnings ratio of 13.52, a PEG ratio of 0.30 and a beta of 0.19. Bristol Myers Squibb has a 12-month low of $42.52 and a 12-month high of $68.64. The business has a 50-day moving average price of $64.63 and a 200 day moving average price of $60.25. The company has a current ratio of 1.53, a quick ratio of 1.38 and a debt-to-equity ratio of 1.89.

Bristol Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 EPS for the quarter, beating analysts’ consensus estimates of $1.60 by $0.44. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. The company had revenue of $12.97 billion for the quarter, compared to analysts’ expectations of $11.74 billion. During the same quarter in the prior year, the company posted $1.46 earnings per share. Bristol Myers Squibb’s revenue for the quarter was up 5.7% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. Sell-side analysts expect that Bristol Myers Squibb will post 6.95 EPS for the current year.

Bristol Myers Squibb Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, November 2nd. Stockholders of record on Friday, October 2nd will be given a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a dividend yield of 4.1%. The ex-dividend date of this dividend is Friday, October 2nd. Bristol Myers Squibb’s dividend payout ratio is currently 55.51%.

About Bristol Myers Squibb

Bristol Myers Squibb (NYSE:BMY) is a global biopharmaceutical company that discovers, develops and commercializes prescription medicines. Its research and commercial activities focus primarily on oncology, hematology, immunology, cardiovascular disease and neuroscience. The company serves patients and healthcare providers in the United States and international markets.

Bristol Myers Squibb’s portfolio includes medicines such as Opdivo and Yervoy for certain cancers, Eliquis for the prevention of blood clots and stroke, Revlimid and Pomalyst for blood cancers, and Abraxane for certain solid tumors.